Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eli Lilly And Co (LLY) vs Toyota Motor Corp (TM) Price & Performance

Eli Lilly And CoTrade
Toyota Motor CorpTrade

Price performance (Past 24H)

Key statistics

Eli Lilly And Co vs Toyota Motor Corp — how do they compare? Eli Lilly And Co trades at $1,217.71 (market cap $1.08T), while Toyota Motor Corp trades at $188.23 (market cap $221.79B). The key difference: Eli Lilly And Co is far larger — about 4.9× Toyota Motor Corp's market cap, and Toyota Motor Corp pays the higher dividend (3.3%). Which is the better fit depends on your goals.

LLYTM
Market Cap
$1.08T$221.79B
Sector
HealthConsumer Cyclical
52-Week High
$1.24K$248.29
52-Week Low
$639.43$166.50
Enterprise Value
$1.13T$414.06B
Dividend Yield
0.57%3.3%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,231.58, up 3.87% in the past 24 hours, reflecting strong momentum near its 52-week high. The stock exhibits bullish technical signals with robust fundamentals, including 48% revenue growth in Q2 2026 and a net income margin of 33.53%. Recent news highlights legal actions against black-market drug sales and positive analyst sentiment following earnings beats.

Outlook remains positive with a consensus price target of $1,380, though high valuation ratios (P/E 40.79) and regulatory risks pose challenges. Earnings growth and pipeline advancements, like retatrutide, drive upside potential, but investors should monitor competitive pressures and execution risks.

Toyota Motor Corp

Toyota Motor (TM) trades at $188.97, up 0.1% on the day, with a bullish technical signal from moving averages. The stock presents attractive valuation metrics, including a P/E of 8.53 and P/B of 0.95, trading below book value. Recent quarterly earnings have consistently beaten expectations, though Q1 2026 results missed estimates due to higher costs, as reported by Zacks Investment Research on August 6, 2026. Cash flow trends show volatility, with a net outflow in 2025 but a projected recovery in 2026.

The outlook is mixed; strong fundamentals and analyst buy ratings support upside, but risks include recall costs, China sales weakness, and margin pressure. Institutional sentiment is cautiously optimistic, with no sell ratings among covered analysts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY

About Toyota Motor Corp

Founded in 1937, Toyota is one of the world's largest automakers with 10.38 million units sold at retail in fiscal 2022 across its light vehicle brands. Brands include Toyota, Lexus, Daihatsu, and truck maker Hino.

Read more on TM